Sequential Intragastric Balloon Followed By GLP-1 Receptor Agonist Therapy in Obesity: A Comparative Study of 12-Month Weight Loss Outcomes.

Teke E, Öztürk S, Ulutaş ME, Yaman S, Gümüştekin B, Akbay A, Bodakçı E

Obesity surgery23 Apr 2026

PMID42026424DOI10.1007/s11695-026-08698-yPepBankPUB-42026424

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity, semaglutide alone gave clinically meaningful weight loss at 6 months.
In plain wordsIn adults with obesity, semaglutide alone led to clinically meaningful weight loss at 6 months.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss at 6 months, semaglutide alone
Study
n = 48
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
All treatment strategies resulted in clinically meaningful weight loss at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included adult patients treated with IGB alone, GLP-1 RAs (semaglutide) alone, or a sequential approach consisting of IGB followed by semaglutide between January 2024 and March 2025.
Summary · context
A total of 107 patients were analyzed (IGB n = 37; GLP-1 RAs n = 48; IGB + GLP-1 RAs n = 22).
Report a problemFND-4202642401
02HumanObservational studyEfficacy outcome
In adults with obesity, semaglutide alone gave 8.5% total weight loss at 12 months.
In plain wordsIn adults with obesity, semaglutide alone gave 8.5% total weight loss after 12 months.
Peptide
Semaglutide
Outcome
DecreaseTotal weight loss (TWL%) at 12 months, semaglutide alone
Study
n = 48
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
TWL%
8.5%
semaglutide alone, 12 months
Source sentences
Summary
At 12 months, the sequential IGB + GLP-1 RAs group achieved significantly greater TWL% compared with both IGB and GLP-1 RAs monotherapy (23.4% vs. 13.2% and 8.5%, respectively; p < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included adult patients treated with IGB alone, GLP-1 RAs (semaglutide) alone, or a sequential approach consisting of IGB followed by semaglutide between January 2024 and March 2025.
Summary · context
A total of 107 patients were analyzed (IGB n = 37; GLP-1 RAs n = 48; IGB + GLP-1 RAs n = 22).
Report a problemFND-4202642402
03HumanObservational studyEfficacy outcome
In adults with obesity, a balloon followed by semaglutide gave greater 12-month total weight loss than a balloon alone.
In plain wordsIn adults with obesity, a balloon followed by semaglutide gave more weight loss at 12 months than a balloon alone.
Peptide
Semaglutide
Outcome
DecreaseTWL% at 12 months, balloon then semaglutide versus balloon alone
Study
n: not reported in source
Comparator
Intragastric balloon alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 3 months of semaglutide after balloon removal at 6 monthsAs given in this study (human).
Measurements
TWL%
23.4%
balloon then GLP-1 RA
TWL%
13.2%
balloon alone
Source sentences
Summary
At 12 months, the sequential IGB + GLP-1 RAs group achieved significantly greater TWL% compared with both IGB and GLP-1 RAs monotherapy (23.4% vs. 13.2% and 8.5%, respectively; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the sequential group, the balloon was removed at 6 months and semaglutide was administered for 3 months thereafter.
Summary · context
This retrospective cohort study included adult patients treated with IGB alone, GLP-1 RAs (semaglutide) alone, or a sequential approach consisting of IGB followed by semaglutide between January 2024 and March 2025.
Summary · context
A total of 107 patients were analyzed (IGB n = 37; GLP-1 RAs n = 48; IGB + GLP-1 RAs n = 22).
Report a problemFND-4202642403

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

04HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, a sequential regimen of a balloon then semaglutide gave greater 12-month total weight loss than semaglutide alone.
In plain wordsIn adults with obesity, a balloon followed by semaglutide gave more weight loss at 12 months than semaglutide alone.
Peptide
Semaglutide
Outcome
DecreaseTWL% at 12 months, balloon then semaglutide versus semaglutide alone
Study
n: not reported in source
Comparator
Semaglutide alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
TWL%
23.4%
balloon then GLP-1 RA
TWL%
8.5%
semaglutide alone
Source sentences
Summary
At 12 months, the sequential IGB + GLP-1 RAs group achieved significantly greater TWL% compared with both IGB and GLP-1 RAs monotherapy (23.4% vs. 13.2% and 8.5%, respectively; p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
In the sequential group, the balloon was removed at 6 months and semaglutide was administered for 3 months thereafter.
Summary · context
This retrospective cohort study included adult patients treated with IGB alone, GLP-1 RAs (semaglutide) alone, or a sequential approach consisting of IGB followed by semaglutide between January 2024 and March 2025.
Summary · context
A total of 107 patients were analyzed (IGB n = 37; GLP-1 RAs n = 48; IGB + GLP-1 RAs n = 22).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4202642404
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with obesity, weight regain between 6 and 12 months occurred in the balloon-alone and semaglutide-alone groups pooled, but not in the sequential group.
In plain wordsIn adults with obesity, people on a balloon alone or semaglutide alone regained weight between 6 and 12 months; the sequential group did not.
Peptide
Semaglutide
Outcome
IncreaseWeight regain between 6 and 12 months in monotherapy groups
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Weight regain between 6 and 12 months was observed in the monotherapy groups, whereas continued weight loss was maintained in the sequential group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included adult patients treated with IGB alone, GLP-1 RAs (semaglutide) alone, or a sequential approach consisting of IGB followed by semaglutide between January 2024 and March 2025.
Summary · context
A total of 107 patients were analyzed (IGB n = 37; GLP-1 RAs n = 48; IGB + GLP-1 RAs n = 22).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4202642405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.